Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in BRAF-mutated Anaplastic Thyroid Cancer
NCT06079333Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in anaplastic thyroid cancer (ATC), sponsored by Leiden University Medical Center. Started Jan 2023; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT06079333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079333.